Botox still looking good on 30th anniversary
Botox and Botox Cosmetic (onabotulinumtoxinA) hold 14 therapeutic and aesthetic indications combined, more than any other neurotoxin in the world.
Allergan has commemorated the beginning of the 30th anniversary celebration for BOTOX this year with the ringing of the New York Stock Exchange opening bell, on 16 December.
Over the past 30 years, more than 100 million vials of Botox and Botox Cosmetic have been manufactured worldwide, providing a trusted and effective treatment option for various therapeutic and aesthetic uses. With two additional FDA approvals this year for therapeutic indications of pediatric upper limb spasticity and pediatric lower limb spasticity, excluding spasticity caused by cerebral palsy, Botox and Botox Cosmetic now proudly hold 14 therapeutic and aesthetic indications combined, reinforcing its leadership in neurotoxin science.
"This incredible milestone underscores our constant focus on innovation and motivates us to further build on our 30 years of research and development efforts for Botox," said Mitchell F. Brin, Senior Vice President Global Drug Development, Chief Scientific Officer, Botox & Neurotoxins. "For three decades, our team has been dedicated to manufacturing and delivering Botox from an unparalleled state-of-the-art facility, abiding by the strictest quality and safety standards. As we now look forward to the next 30 years and beyond, we maintain our commitment to serve patients worldwide across a wide spectrum of diseases and clinical needs."
Botox was first FDA-approved in 1989 for two rare eye muscle disorders – blepharospasm and strabismus in adults, making it the world's first botulinum toxin type A product to be approved. Since then, BOTOX has continued to innovate which has led to the FDA's approval of 11 therapeutic indications, including Chronic Migraine, overactive bladder, incontinence associated with a neurologic condition, cervical dystonia, adult upper limb spasticity, adult lower limb spasticity, severe underarm sweating (axillary hyperhidrosis), and most recently, pediatric upper limb spasticity and pediatric lower limb spasticity, excluding spasticity caused by cerebral palsy.
"Our ongoing collaboration with Allergan and the approval of Botox in 2000 as a first-line treatment for cervical dystonia have been very important to us and have brought hope to the cervical dystonia community," said Art Kessler, President of the Board, Dystonia Medical Research Foundation (DMRF). "We value our shared commitment to raising awareness of the disease, potential treatment options, and the importance of talking to your doctor."
As the first neurotoxin treatment to be approved for aesthetic use, Botox Cosmetic remains a category leader, backed by 17 years of data. Receiving its first FDA approval in 2002 to temporarily improve the appearance of moderate to severe glabellar lines (frown lines between the eyebrows), Botox Cosmetic is also approved for the temporary improvement in the appearance of moderate to severe crow's feet and forehead lines in adults.
With more than 3,900 articles on Botox and Botox Cosmetic published in scientific and medical journals, and over 115 sponsored studies, Botox neurotoxin is one of the most widely researched medicines in the world. Botox continues to be a leader in its category as it carries 28 indications worldwide, with approval for use in 100 different countries.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance